Nanotech breakthrough boosts CBD absorption by up to 20%

Scientists have developed a new delivery system that significantly improves how well our bodies can absorb cannabidiol (CBD) when taken orally. The study tested nanostructured lipid carriers (NLCs) - tiny fat-based particles designed to transport CBD more effectively through the digestive system. Researchers compared these advanced carriers against simple hemp seed oil formulations using both CBD extract and pure CBD isolate. The results showed that NLC formulations achieved 86-94% bioaccessibility, meaning nearly all the CBD could potentially be absorbed by the body, compared to only 76-77% for standard oil-based formulations. This represents a meaningful improvement in how much CBD actually becomes available for therapeutic use.

The research also addressed an important safety concern: pure CBD showed dose-dependent toxicity to intestinal cells in laboratory tests, but when packaged in NLCs, the formulations maintained over 80% cell viability, suggesting better tolerability. Importantly, both CBD-rich extract and pure CBD isolate performed equally well in the NLC system, giving consumers and manufacturers flexibility in choosing between whole-plant extracts or isolated compounds. While these laboratory results are promising for developing more effective CBD products - whether as functional foods or therapeutic formulations - the researchers emphasize that human trials are still needed to confirm these benefits translate to real-world use. For cannabis users, this technology could eventually mean lower doses are needed to achieve desired effects, potentially reducing costs and side effects.